canertinib dihydrochloride has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Conrad, CA; Edwards, CL; Forman, A; Freedman, RS; Grothey, A; Grove, W; Hasenburg, A; Kavanagh, JJ; Kudelka, AP; Meyers, CA; Varma, D; Verschraegen, CF | 1 |
| Conrad, CA; Gelke, CK; Grove, W; Kudelka, AP; Meyers, CA; Pazdur, R | 1 |
2 trial(s) available for canertinib dihydrochloride and Cancer of Ovary
| Article | Year |
|---|---|
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Carbamates; Carcinoma; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dyspnea; Female; Humans; Hyponatremia; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Phlebitis; Pyrazines; Pyridines; Survival Rate; Treatment Outcome | 1998 |
Neurotoxicity of CI-980, a novel mitotic inhibitor.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Cognition; Cognition Disorders; Colorectal Neoplasms; Female; Humans; Male; Memory; Memory Disorders; Middle Aged; Neuropsychological Tests; Neurotoxins; Ovarian Neoplasms; Pyrazines; Pyridines | 1997 |